Rocket Pharmaceuticals, Inc. (RCKT Quick QuoteRCKT - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $13.70 –$18.44 in the past one-month time frame, witnessed a sharp increase yesterday.

The move came after the company announced an exclusive, worldwide license agreement with REGENXBIO to develop and commercialize gene therapy treatments for Danon disease by using latter’s NAV AAV9 vector.

The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Rocket Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Rocket Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Inotek Pharmaceuticals Corporation Price

Investors interested in the Medical – Biomedical and Genetics industry may consider Alexion Pharmaceuticals, Inc. , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is RCKT going up? Or down? Predict to see what others think:Up or Down

The Hottest Tech Mega-Trend of All
 
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>